A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis
about
The pan-chemokine inhibitor NR58-3.14.3 abolishes tumour necrosis factor-alpha accumulation and leucocyte recruitment induced by lipopolysaccharide in vivoComparison of the solution conformations of a cell-adhesive peptide LBE and its reverse sequence EBL.Rational design of nonnatural peptides as high-affinity ligands for the HLA-B*2705 human leukocyte antigenA rational design approach for developing immunomodulators based on CD4 and CD8.Retro-inverso carbohydrate mimetic peptides with annexin1-binding selectivity, are stable in vivo, and target tumor vasculatureFunctional epitope analysis of the human CD4 molecule: antibodies that inhibit human immunodeficiency virus type 1 gene expression bind to the immunoglobulin CDR3-like region of CD4A computer screening approach to immunoglobulin superfamily structures and interactions: discovery of small non-peptidic CD4 inhibitors as novel immunotherapeuticsThe affinity-selection of a minibody polypeptide inhibitor of human interleukin-6.A retro-inverso peptide corresponding to the GH loop of foot-and-mouth disease virus elicits high levels of long-lasting protective neutralizing antibodies.Recombinant T cell receptor ligands: immunomodulatory, neuroprotective and neuroregenerative effects suggest application as therapy for multiple sclerosisAutoimmunity associated with TGF-beta1-deficiency in mice is dependent on MHC class II antigen expression.T-cell response dynamics in animal models of multiple sclerosis: implications for immunotherapies.Peptidomimetics: modifying peptides in the pursuit of better vaccines.Synthetic peptides derived from the variable regions of an anti-CD4 monoclonal antibody bind to CD4 and inhibit HIV-1 promoter activation in virus-infected cells.Efficient CD4 binding and immunosuppressive properties of the 13B8.2 monoclonal antibody are displayed by its CDR-H1-derived peptide CB1.Identification of a human CD4-CDR3-like surface involved in CD4+ T cell function.Immunomodulatory peptides with high binding affinity for class II MHC molecules for the prevention of graft-versus-host disease.Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1.Recent advances in graft-versus-host disease (GVHD) prevention.Immunoglobulin superfamily proteins: structure, mechanisms, and drug discovery.Molecular recognition of peptide and non-peptide ligands by the extracellular domains of neurohypophysial hormone receptors.Synthetic CD4 exocyclic peptides antagonize CD4 holoreceptor binding and T cell activation.Penetratin and derivatives acting as antibacterial agents.A5, a new small-molecule inhibitor of CD4 D1 obtained from a computer-aided screening method, contributes to the inhibition of CD4+ T-cell function.The potential of retro-inverso peptides as synthetic vaccines.Exploration of requirements for peptidomimetic immune recognition. Antigenic and immunogenic properties of reduced peptide bond pseudopeptide analogues of a histone hexapeptide.Interface PeptidesStructure based design and characterization of peptides that inhibit IgE binding to its high-affinity receptor
P2860
Q24682472-9DA3F36B-BC14-4F01-B538-16B0EC77FEC6Q31453238-A0F8DA2A-000F-40B0-80F7-0F2461042E6EQ34727706-CADB7E04-0002-490C-8F2A-F5A4CA3789A8Q35042491-588FFB59-28FF-4A5B-B31F-E13E10F1FDA6Q35061044-657F1E7A-7120-4318-A792-F7845B1F0363Q35850465-83C69051-804B-4D7F-9ADA-43C90345DA06Q35899665-4F0D4273-8EDB-4D53-B235-2B7B52A80114Q36726385-C719FCB4-B5FC-4475-B30E-1AE2E476F6A3Q36822090-A662861F-7667-4C83-A9C1-1407D73B3767Q37068900-6D1FD2B8-A58F-4C7C-BC79-B5F787674979Q37361208-FB4273DD-370D-4F28-8435-956168A77578Q37754572-83B3936B-E56D-4730-8252-B796EE9A37DFQ37844539-FF1D2F6F-7104-4E7E-A257-B61BA334F029Q38328986-34F629D5-7863-4465-A632-061B7E84A56DQ40768927-5900F305-2201-4044-89DF-FAD17181B990Q41168237-06F5E470-A2C9-40EF-A7B6-358278B0C691Q41342013-B11DCF27-B8FD-47F7-95FD-D706196B5BC4Q41417560-040D583B-AE66-4D8F-BBF6-D7A8590C2843Q41561701-E24DCFB9-9CF8-49CE-97D1-F53C24BE1F87Q41753464-FD656B8E-65F2-4A30-ACC9-2D32DB2B21AEQ42158406-C95B2E2B-47BB-47C0-B4F7-27758512CD20Q47961040-7BECFDD8-A3BB-4E87-8DB1-A7D585986B69Q51071562-2CDEA1BB-0C37-4C0A-8286-AD73839F911EQ51909987-A54A8E2B-579B-41CE-B769-33930CF37055Q53852768-3A0EDCA7-56F5-4D42-BEAE-3F6859BFE307Q53977880-12C25FC1-EAEE-4940-A7C1-04A273D5A9FFQ57721879-55E0101A-731F-4B57-BD99-2606245E43D0Q58428845-76996893-6428-4562-A22B-F18882AA5B9F
P2860
A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis
description
1994 nî lūn-bûn
@nan
1994 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis
@ast
A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis
@en
A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis
@nl
type
label
A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis
@ast
A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis
@en
A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis
@nl
prefLabel
A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis
@ast
A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis
@en
A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis
@nl
P2093
P356
P1433
P1476
A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis
@en
P2093
B A Jameson
J C Marini
J M McDonnell
R Korngold
P2888
P356
10.1038/368744A0
P407
P577
1994-04-21T00:00:00Z
P6179
1000663713